«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 24

Page:

4572-4575

Research Field:

Publishing date:

Info

Title:

Association between genetic polymorphisms of glutathione S-transferase P1 and clinical outcomes of oxaliplatin plus capecitabine chemotherapy in patients with metastatic gastric cancer

Author(s):

DONG Ningning¹; HAN Lei²

1.Department of Gastroenterology,Beijing Friendship Hospital,Capital Medical University/National Clinical Research Center of Gastrointestinal Disease/Beijing Digestive Disease Center/Beijing Key Laboratory for Precancerous Lesion of Digestive Diseases,Bei

Keywords:

metastatic gastric cancer; glutathione S-transferase P1; single nucleotide polymorphism; drug therapy

PACS:

R735.2

DOI:

10.3969/j.issn.1672-4992.2023.24.016

Abstract:

Objective:To analyze the association between genetic polymorphisms of glutathione S-transferase P1 (GSTP1) rs1695 and clinical outcomes of oxaliplatin plus capecitabine chemotherapy in patients with metastatic gastric cancer.Methods:102 patients with metastatic gastric cancer were enrolled.They received oxaliplatin in combination with capecitabine chemotherapy (XELOX regimen).GSTP1 rs1695 genotype was detected by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF).The relationship between clinicopathological characteristics (including age,gender,tumor differentiation,location,Eastern Cooperative Oncology Group performance status,and TNM stage) and GSTP1 rs1695 genotypes and clinical outcomes ［including objective response rate (ORR) and progression-free survival (PFS)］ was analyzed.Results:Among these enrolled patients,73 patients (71.6%) carried GSTP1 rs1695 AA genotype,27 patients (26.5%) AG genotype,and 2 patients (2.0%) GG genotype.Patients harboring GG/AG genotype had both a statistically higher objective response rate than those with AA genotype (69.0% vs 43.8%，P=0.022),and longer progression-free survival［6.1 months (95%CI：5.2~7.0) vs 5.1 months (95%CI：4.6~5.6)，P=0.028］.None of the clinicopathological characteristics was related to tumor response,whereas,tumor differentiation and TNM stage were associated with progression-free survival (P＜0.05).Cox regression analysis suggested that tumor differentiation,TNM stage and GSTP1 rs1695 were independent prognostic factors of progression-free survival.Conclusion:GSTP1 rs1695 genotype is closely related to the clinical outcomes of oxaliplatin plus capecitabine chemotherapy in patients with metastatic gastric cancer,which represents a further step towards individualized therapy.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］ JOSHI SS,BADGWELL BD.Current treatment and recent progress in gastric cancer［J］.CA Cancer J Clin,2021,71(3):264-279.
［3］ SA JK,HONG JY,LEE IK,et al.Comprehensive pharmacogenomic characterization of gastric cancer［J］.Genome Med,2020,12(1):17.
［4］ JIN X,JIANG ML,WU ZH,et al.Progress of individualized chemotherapy for gastric carcinoma under the guidance of genetic testing［J］.Curr Med Chem,2020,27(14):2322-2334.
［5］ CHEN Y,LI B,WANG J,et al.Identification and verification of the prognostic value of the glutathione S-transferase Mu genes in gastric cancer［J］.Oncol Lett,2020,20(4):100.
［6］ CORIC V,MILOSEVIC I,DJUKIC T,et al.GSTP1 and GSTM3 variant alleles affect susceptibility and severity of COVID-19［J］.Front Mol Biosci,2021,8:747493.
［7］ EL-DEEK SEM,ABDEL-GHANY SM,HANA RS,et al.Genetic polymorphism of lysyl oxidase,glutathione S-transferase M1,glutathione-S-transferase T1,and glutathione S-transferase P1 genes as risk factors for lung cancer in Egyptian patients［J］.MolBiol Rep,2021,48(5):4221-4232.
［8］ STOJKOVIC LALOSEVIC ML,CORIC VM,PEKMEZOVIC TD,et al.Deletion and single nucleotide polymorphisms in common glutathione-S transferases contribute to colorectal cancer development［J］.Pathol Oncol Res,2019,25(4):1579-1587.
［9］ FARMOHAMMADI A,ARAB-YARMOHAMMADI V,RAMZANPOUR R.Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility［J］.Asian Pac J Cancer Prev,2020,21(4):1167-1172.
［10］ SANTRIC V,DJOKIC M,SUVAKOV S,et al.GSTP1 rs1138272 polymorphism affects prostate cancer risk［J］.Medicina (Kaunas),2020,56(3):128.
［11］ SONG Y,CHEN J,LIU K,et al.Glutathione S-transferase Pi 1 (GSTP1) gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer:Evidence from a systematic review and meta-analysis based on 34 case-control studies［J］.Gene,2019,719:144077.
［12］ IBARROLA-VILLAVA M,MARTIN-GONZALEZ M,LAZARO P,et al.Role of glutathione S-transferases in melanoma susceptibility:association with GSTP1 rs1695 polymorphism［J］.Br J Dermatol,2012,166(6):1176-1183.
［13］ DE LUCA A,PARKER LJ,ANG WH,et al.A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1［J］.Proc Natl Acad Sci USA,2019,116(28):13943-13951.
［14］ SIMIC P,PLJESA I,NEJKOVIC L,et al.Glutathione transferase P1:Potential therapeutic target in ovarian cancer［J］.Medicina (Kaunas),2022,58(11):1660.
［15］ HUANG ZH,HUA D,DU X.Polymorphisms in p53,GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy［J］.Cancer Chemother Pharmacol,2009,64(5):1001-1007.
［16］ LIU YP,LING Y,QI QF,et al.Genetic polymorphisms of ERCC1-118,XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy［J］.Mol Med Rep,2013,7(6):1904-1911.
［17］ KATAYANAGI S,KATSUMATA K,MORI Y,et al.GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy［J］.Oncol Lett,2019,17(3):2897-2904.
［18］ OTT K,LORDICK F,BECKER K,et al.Glutathione-S-transferase P1,T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer:GSTM1-present genotype is associated with better prognosis in completely resected patients［J］.Int J Colorectal Dis,2008,23(8):773-782.
［19］ PATEL JN,JIANG C,OWZAR K,et al.Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (alliance)［J］.Pharmacogenet Genomics,2021,31(9):215-220.
［20］ CORDOVA-DELGADO M,BRAVO ML,CUMSILLE E,et al.A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer［J］.BMC Cancer,2021,21(1):1030.

Memo

Memo:

National Natural Science Foundation of China(No.82070575）；国家自然科学基金（编号：82070575）；北京市优秀人才培养资助计划（编号：2015000021469G232）

Common functions

Last Update: 1900-01-01